Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023418 (
leukemia
)
93,477
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In the present study the therapeutic efficacy and the side effects of two antiretroviral compounds used in human acquired immunodeficiency syndrome (AIDS) research, 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine,
Retrovir
) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA), were investigated in the treatment of cats naturally infected with feline immunodeficiency virus (FIV) and cats naturally infected with feline
leukemia
virus (FeLV). AZT was administered subcutaneously at a dose of 5 mg kg-1 body weight every 12 h and PMEA was administered subcutaneously at a dose of 2.5 mg kg-1 body weight every 12 h during a 3 week hospitalization. The therapeutic efficacy of both compounds was investigated. There was a stronger potency of PMEA than of AZT on the regression of stomatitis in FIV and in FeLV infected cats. In addition, in FIV infection PMEA had a stronger effect on the improvement of the general clinical status. Both antiretroviral compounds were potent agents to improve the immunologic status of FIV infected cats by raising the CD4/CD8 ratio. In FeLV infection PMEA and AZT appeared to reduce antigenemia. The hematological side effects caused by PMEA were severe and stronger than those of AZT. Therefore the advantage of PMEA in clinical and immunologic improvement was diminished by the hematologic disorders, which do not allow long term treatment with this drug in the dose used.
...
PMID:Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. 136 8
No commercial vaccine [correction of vacine] exists for feline immunodeficiency virus (FIV), and although feline
leukemia
virus (FeLV) vaccines are available, they are neither 100% effective nor used in all cats. These realities clearly indicate the veterinarian will be required to treat either FeLV- or FIV-positive cats for some time to come. The management of FIV- or FeLV-positive cats may require supportive therapies as well as virus-specific therapies such as zidovudine (AZT;
Retrovir
, Burroughs Wellcome, Research Triangle Park, NC).
...
PMID:Caring for the retrovirus infected cat. 882 May 95
This study is to investigate the synergistic effect of Anglica polysaccharide sulfate (APS-1) and
Combivir
, an anti-AIDS drug, on murine
leukemia
virus in vivo. As the results shown, the virus replication was significantly decreased by the combination of APS-1 and
Combivir
, which tended to be further decreased (58% inhibition) when compared with that of
Combivir
alone (51% inhibition). Furthermore, both the percentage of CD4(+) cells and CD4(+)/CD8(+) ratio in peripheral blood cells were significantly enhanced by this combined administration, while the CD4(+) cells was only slightly increased and CD4(+)/CD8(+) ratio was not affected by
Combivir
alone. Additionally, combination of APS-1 and
Combivir
also alleviated the toxicity of
Combivir
. APS-1 not only increased the survival rate of mice administered with LD(50) dose of
Combivir
, but also reduced the hematologic toxicity induced by
Combivir
, RBC, HGB and PLT were restored to normal level. These results suggest that APS-1 had synergistic effect with
Combivir
, which provided new insight into the potential clinical use of polysaccharide sulfate in anti-AIDS field.
...
PMID:Synergistic antivirus effect of combined administration of Combivir with Angelica polysaccharide sulfate. 2315 62
Tropical spastic paraparesis (TSP) or human T-cell
leukemia
virus-type 1 (HTLV-I)-associated myelopathy is caused by human T-lymphotropic virus type 1. It is a slow, progressive spastic paraparesis with significant morbidity and causing profound repercussions on quality of life. No therapies have been found to persistently improve the outcome in these patients. We present a patient with HTLV-1-associated myelopathy/TSP (HAM/TSP) who was treated with
Combivir
(lamivudine-zidovudine, GlaxoSmithKline, London, UK). She was walker-dependent for several years but, soon after treatment with lamivudine-zidovudine, was able to walk using only a cane. The role of lamivudine-zidovudine should be investigated further in this patient population.
...
PMID:Tropical spastic paraparesis treated with Combivir (lamivudine-zidovudine). 2347 75